Samsung Biologics has launched a 1.81 billion dollar all-cash bid to acquire Swiss pharmaceutical manufacturer PolyPeptide Group, marking the largest merger-and-acquisition deal ever completed by a Korean biotech company and signaling the South Korean giant's aggressive push into the booming market for obesity and diabetes drugs.

The tender offer, announced Monday morning, values PolyPeptide at 1.46 billion Swiss francs and offers shareholders CHF 44.31 per share—a 35 percent premium over the company's closing price on Friday. The deal has already secured unanimous backing from PolyPeptide's board and an irrevocable commitment from its largest shareholder, representing approximately 55.65 percent of outstanding shares.

Betting Big on GLP-1 Drugs

The acquisition positions Samsung Biologics to capitalize on one of the pharmaceutical industry's hottest growth areas: peptide-based therapeutics. The GLP-1 drug class—which includes blockbuster obesity and diabetes treatments like Ozempic and Wegovy—has driven explosive demand for peptide manufacturing capacity, and contract producers like PolyPeptide have found themselves unable to keep up.

PolyPeptide operates manufacturing facilities across Sweden, Belgium, France, the United States, and India, with a corporate headquarters in Switzerland and an innovation center in Strasbourg. The company has produced more than 1,000 therapeutic peptides over its 70-year history, building deep expertise that Samsung Biologics aims to leverage.

A Multi-Modality Strategy

For Samsung Biologics, the acquisition represents a significant expansion beyond its traditional focus on antibodies and antibody-drug conjugates. The company has emerged as one of the world's largest contract development and manufacturing organizations (CDMOs), operating massive biologic production facilities in South Korea that serve major pharmaceutical companies globally.

Adding peptide capabilities gives Samsung Biologics a portfolio spanning multiple drug modalities, making it a more attractive one-stop partner for pharmaceutical companies developing diverse pipelines. The strategy mirrors broader industry trends, as drugmakers increasingly seek CDMO partners capable of handling various drug types.

The deal also expands Samsung Biologics' geographic footprint beyond Asia, giving it direct manufacturing presence in the United States and Europe—critical markets where local production can offer regulatory and supply-chain advantages.

A Premium Price for Premium Assets

While the 35 percent premium represents a significant price tag, the valuation reflects the strategic scarcity of quality peptide manufacturing capacity. The obesity drug boom has overwhelmed existing production infrastructure, with Eli Lilly and Novo Nordisk both investing billions to build proprietary peptide facilities amid persistent supply shortages.

PolyPeptide reported preliminary first-half 2026 results alongside the acquisition announcement, showing 41.6 percent revenue growth to EUR 236.6 million and an EBITDA margin of 20.7 percent. The company upgraded its full-year guidance, suggesting robust demand continues.

The transaction is expected to close by year-end 2026, subject to regulatory approvals and a minimum acceptance threshold of 66 and two-thirds percent from shareholders.

Industry Implications

The deal underscores the intense competition for pharmaceutical manufacturing capacity as the industry races to meet demand for next-generation obesity treatments. Analysts estimate the GLP-1 drug market could exceed 100 billion dollars annually by 2030, creating enormous incentives for scale-up investments.

For Samsung Biologics, the acquisition represents a calculated bet that peptide demand will only accelerate as applications expand beyond diabetes and obesity into cardiovascular disease, liver conditions, and potentially cancer. Success would cement the company's position as a truly multi-modality global CDMO capable of serving any pharmaceutical development program.

The deal marks Samsung Biologics' largest acquisition to date and signals confidence in the peptide manufacturing space just as established players struggle to meet burgeoning demand.